LBA40_PR ARIEL3: a phase 3, randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma (OC).
Authors
Ledermann, JOza, A
Lorusso, D
Aghajanian, C
Oaknin, A
Dean, A
Colombo, N
Weberpals, J
Clamp, Andrew R
Scambia, G
Leary, A
Holloway, R
O'Malley, D
Cameron, T
Maloney, L
Goble, S
Lin, K
Sun, J
Giordano, H
Coleman, R
Affiliation
Gynaecological Oncology, University College London Cancer Institute and UCL Hospitals, LondonIssue Date
2017-09
Metadata
Show full item recordCitation
LBA40_PR ARIEL3: a phase 3, randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma (OC). 2017, 28(suppl_5): Ann OncolJournal
Annals of OncologyDOI
10.1093/annonc/mdx440.034Additional Links
http://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx440.034/4109946/LBA40PRARIEL3-A-phase-3-randomised-doubleblindType
Meetings and ProceedingsLanguage
enISSN
0923-75341569-8041
ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdx440.034